REAL-WORLD CARDIAC SAFETY OF ANTI-HER2 THERAPIES IN ELDERLY PATIENTS WITH HER2+/HR-METASTATIC BREAST CANCER: A RETROSPECTIVE COHORT STUDY USING SEER-MEDICARE DATA 2012-2016

被引：0
|
作者：
Ou, Z. [1 ]
Nohria, A. [2 ]
Spring, L. M. [3 ]
Seeger, J. D. [4 ]
Doucette, J. [5 ]
Murimi-Worstell, I. B. [5 ]
机构：
[1] MCPHS Univ, Belmont, MA USA
[2] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[3] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[4] Optum, Boston, MA USA
[5] MCPHS Univ, Boston, MA USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
SA33
引用
收藏
页码：S610 / S610
页数：1
相关论文
共 50 条
  • [1] Survival of elderly patients with HER2+/HR- metastatic breast cancer in clinical practice: SEER-Medicare data 2012-2016.
    Ou, Zhonghui
    Spring, Laura
    Nohria, Anju
    Seeger, John D.
    Murimi-Worstell, Irene
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study
    Gong, Chengcheng
    Zhao, Yannan
    Wang, Biyun
    Hu, Xichun
    Wang, Zhonghua
    Zhang, Jian
    Zhang, Sheng
    ONCOTARGET, 2017, 8 (35) : 59810 - 59822
  • [3] Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis
    Abby B. Statler
    Brian P. Hobbs
    Wei Wei
    Annie Gupta
    Cassann N. Blake
    Zeina A. Nahleh
    Scientific Reports, 9
  • [4] The characteristics of HER2-positive microinvasive breast cancer and the necessity of chemotherapy and anti-HER2 therapy in these patients: A real-world study
    Lan, B.
    Lv, D.
    Guo, C.
    Feng, Z.
    Fan, Y.
    Ma, F.
    Xu, B.
    ANNALS OF ONCOLOGY, 2023, 34 : S286 - S286
  • [5] Results of a retrospective study on the efficacy and safety of alpelisib in patients with HR+/HER2-metastatic breast cancer in real-world clinical practice
    Sultanbaev, Alexander Valerievich
    Kolyadina, Irina Vladimirovna
    Menshikov, Konstantin
    Musin, Shamil
    Sultanbaeva, Nadezda
    Lipatov, Danila
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Effectiveness of second-line anti-HER2 treatment in HER2-positive metastatic breast cancer patients previously treated with trastuzumab: A real-world study
    Zhao, Wei
    Bian, Li
    Wang, Tao
    Zhang, Shaohua
    Li, Jianbin
    Xu, Fengrui
    Jiang, Zefei
    CHINESE JOURNAL OF CANCER RESEARCH, 2020, 32 (03) : 361 - 369
  • [7] Effectiveness of second-line anti-HER2 treatment in HER2-positive metastatic breast cancer patients previously treated with trastuzumab: A real-world study
    Wei Zhao
    Li Bian
    Tao Wang
    Shaohua Zhang
    Jianbin Li
    Fengrui Xu
    Zefei Jiang
    ChineseJournalofCancerResearch, 2020, 32 (03) : 361 - 369
  • [8] Real-world data of HER2-low metastatic breast cancer: A population based cohort study
    Holthuis, Emily I.
    Vondeling, Gerard T.
    Kuiper, Josephina G.
    Dezentje, Vincent
    Rosenlund, Mats
    Overbeek, Jetty A.
    van Deurzen, Carolien H. M.
    BREAST, 2022, 66 : 278 - 284
  • [9] Real-world study of patients with HR+/ HER2-metastatic breast cancer treated with palbociclib and fulvestrant
    Robert, Nicholas
    Chen, Connie
    Doan, Justin
    Venkatasetty, Divea
    Espirito, Janet L.
    Aguilar, Kathleen M.
    FUTURE ONCOLOGY, 2025, 21 (01) : 83 - 94
  • [10] Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study
    Zhang, Qiongwen
    He, Ping
    Tian, Tinglun
    Yan, Xi
    Huang, Juan
    Zhang, Zhang
    Zheng, Hong
    Zhong, Xiaorong
    Luo, Ting
    FRONTIERS IN PHARMACOLOGY, 2023, 14
12345